Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis

Current Rheumatology Reports

Volumn 15, Issue 1, 2013, Pages

  Yaqub, Aaliya ^a,c   Chung, Lorinda ^a,b,c  

^a STANFORD UNIVERSITY   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibodies; Biomarkers; Epidemiology; Pulmonary arterial hypertension; Pulmonary hypertension; Risk factors; Scleroderma; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AUTOANTIBODY;

ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HEMODYNAMICS; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC SCLEROSIS; TELANGIECTASIA;

EID: 84870437106     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0302-2     Document Type: Article

References (50)

1. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest. 2012;141(1):210-1.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43.
3. O'Callaghan DS, Dorfmuller P, Jaïs X, et al. Pulmonary venoocclusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? Presse Med. 2011;40(1 Pt 2):e65-78.
4. Montani D, O'Callaghan DS, Savale L, et al. Pulmonary venoocclusive disease: recent progress and current challenges. Respir Med. 2010;104 Suppl 1:S23-32.
5. McLaughlin VV, Archer SL, Badesch DB, et al. Accf/aha 2009 expert consensus document on pulmonary hypertension: a report of the American college of cardiology foundation task force on expert consensus documents and the American heart association developed in collaboration with the American college of chest physicians; American thoracic society, inc.; and the pulmonary hypertension association. J Am Coll Cardiol. 2009;53(17):1573- 619.
6. de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis. 2008;67:31-6.
7. Launay D, Mouthon L, Hachulla E, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol. 2007;34:1005-11. (Pubitemid 46774846)
8. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940-4. (Pubitemid 46999798)
9. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138(6):1383-94.
10. Chung L, Domsic RT, Lingala B, Steen VD. Better survival in systemic sclerosis-associated pulmonary arterial hypertension patients enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Arthritis Rheum. 2011;63(10S):S673.
11. Ngian G, Stevens W, Byron J, et al. Survival and predictors of mortality in Australian patients with connective tissue diseaseassociated pulmonary arterial hypertension. Arthritis Rheum. 2011;63(10S):S332.
12. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9(5):A311-8.
13. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003;29:239-54. (Pubitemid 36765119)
14. de Azevedo AB, Sampaio-Barros PD, Torres RM, Moreira C. Prevalence of pulmonary hypertension in systemic sclerosis. Clin Exp Rheumatol. 2005;23(4):447-54. (Pubitemid 41447613)
15. Kumar U, Ramteke R, Yadav R. Prevalence and predictors of pulmonary artery hypertension in systemic sclerosis. J Assoc Physicians India. 2008;58:413-7.
16. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52(12):3792-800. (Pubitemid 41798217)
17. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088-93. (Pubitemid 37323574)
18. Barst RJ, McGoon M, Torbicki A. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiology. 2004;43:40S-7.
19. Domsic RT, Chung L, Gomberg-Maitland M, et al. Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): comparison of outcomes in subtypes of pulmonary hypertension. Arthritis Rheum. 2010;62(10S):S245.
20. Hachulla E, de Groote P, Gressin V, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009;60(6):1831-9.
21. Peoples C, Domsic R, Medsger T, et al. Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): racial differences in systemic sclerosis-related pulmonary hypertension. Arthritis Rheum. 2011;63(10S):S272.
22. Avouac J, Airò P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010;37:2290-8.
23. Chang B, Schachna L, White B, et al. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol. 2006;33:269-74. (Pubitemid 43209302)
24. Schachna L,Wigley FM, Chang B, et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest. 2003;124:2098-104. (Pubitemid 38010575)
25. Scorza R, Caronni M, Bazzi S, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci. 2002;966:238-46. (Pubitemid 34729180)
26. Beretta L, Caronni M, Origgi L, et al. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand J Rheumatol. 2006;35:468-71. (Pubitemid 47215719)
27. Cox SR, Walker JG, Coleman M, et al. Isolated pulmonary hypertension in scleroderma. Intern Med J. 2005;35:28-33. (Pubitemid 40254764)
28. Hunzelmann N, Genth E, Krieg T, et al. The registry of the German network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology. 2008;47:1185-92. (Pubitemid 352038224)
29. Hachulla E, Launay D, Mouthon L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest. 2009;136:1211-9.
30. Steen V, Medsger Jr TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48:516-22. (Pubitemid 36278021)
31. Shah AA, Wigley FM. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010;37(1):98-104.
32. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008;58:284-91.
33. Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest. 2008;134(1):146-51. (Pubitemid 352008776)
34. Hsu V, Moreyra AE, Wilson AC, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol. 2008;35:458-65. (Pubitemid 351374421)
35. Shah AA, Chung SE, Wigley FM, et al. Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients. Ann Rheum Dis 2012 Aug 11. doi:10.1136/ annrheumdis-2012-201861.
36. Kampolis C, Plastiras S, Vlachoyiannopoulos P, et al. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol. 2008;37:278-83. (Pubitemid 351962324)
37. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35-42. (Pubitemid 41111469)
38. Steen VD, Lucas M, Fertig N, et al. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with nucleolar antibody. J Rheumatol. 2007;34:2230-5. (Pubitemid 350076884)
39. Aggarwal R, Lucas M, Fertig N, Oddis C, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009;60:1112-8.
40. Graf SW, Hakendorf P, Lester S, et al. South Australian scleroderma register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis. 2012;15(1):102-9.
41. Assous N, Allanore Y, Batteux F, et al. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol. 2005;23:199-204. (Pubitemid 40663000)
42. Marie I, Jouen F, Hellot MF, et al. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol. 2008;158:141-4. (Pubitemid 350221924)
43. Dib H, Tamby MC, Bussone G, et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J. 2012;39(6):1405-14.
44. Negi VS, Tripathy NK, Misra R, et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol. 1998;25:462-6.
45. Grader-Beck T, Boin F, von Gunten S, et al. Antibodies recognizing sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease. Ann Rheum Dis. 2011;70(12):2218-24.
46. Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Resp J. 2010;35(1):95-104.
47. Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther. 2012;14(3):R143.
48. Hummers LK, Hall L, Wigley FM, et al. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol. 2009;36:576-82.
49. Lip GY, von Blann A. Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res. 1997;34:255-65. (Pubitemid 27241568)
50. Barnes T, Gliddon A, Doré CJ, Maddison P, Moots RJ, the QUINs Trial Study Group. Baseline vWF factor predicts the development of elevated pulmonary artery pressure in systemic sclerosis. Rheumatology. 2012;51(9):1606-9.